Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Krishna Institute of Medical Sciences Ltd Share Price
Day's Range
Day's Range
Low
₹748.05
High
₹782.00
Price Summary
| Previous Close | ₹761.65 |
|---|---|
| Day's Range | ₹748.05 - ₹782.00 |
| Open | ₹771.50 |
| 52 Week Range | ₹575.80 - ₹798.40 |
| Volume | 5,92,313 |
| Market Cap | ₹0.03 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 4,534.76 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 101.35 |
| TTM EPS (₹) | 7.51 |
| P/E Ratio | 66.51 |
| Book Value(₹) | 13.12 |
| PAT Margin (%) | 13.67 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 19.04 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 13841.0 | 3459.0 |
| Expenses | N/A | N/A |
| PBT | 4031.0 | 1205.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 3029.0 | 935.0 |
About Krishna Institute of Medical Sciences Ltd
| Founded | 1973 |
|---|---|
| Managing Director | Bhaskara Rao Bollineni |
| NSE Symbol | KIMS |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,51,074.97 | 1,879.90 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,485.96 | 6,755.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,124.14 | 4,386.00 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,16,201.01 | 8,077.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,640.69 | 1,431.55 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,11,589.46 | 1,336.95 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,03,966.32 | 2,273.90 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,03,368.09 | 2,507.00 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 1,02,190.60 | 1,050.05 | 903.00 - 903.00 |
| Zydus Lifesciences Ltd. | 1,01,755.41 | 1,011.25 | 835.50 - 835.50 |
No Records Found
Latest News
Krishna Institute of Medical Sciences informs about updates
Pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, Krishna Institute of Medical Sciences has informed that the company (‘KIMS’) has entered into a non-commercial brand association agreement with Dakshayani Healthcare Services (‘Renova’), a specialized oncology organization with proprietary clinical protocols and expertise in cancer research and academic supervision and has extensive experience in managing cancer centers across India. Under this arrangement, both KIMS and RENOVA will collaborate on a mutual, non-commercial basis, wherein RENOVA will be sharing its clinical expertise, knowledge, and best practices in Oncology care with KIMS. The association is intended to strengthen healthcare delivery standards, particularly in Oncology services, and enhance patient care outcomes.
The above information is a part of company’s filings submitted to BSE.
Krishna Institute of Medical Sciences informs about certificate
Gland Pharma informs about newspaper advertisement
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, Gland Pharma has informed that it enclosed copies of the newspaper advertisement pertaining to Audited Financial Results of the Company for the financial year ended March 31, 2026. The advertisements were published in English and Telugu newspapers.
The above information is a part of company’s filings submitted to BSE.
Dolphin Medical Services submits intimation of open offer
Aurobindo Pharma informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, announced that the Central Drugs Standard Control Organization (CDSCO) has granted Marketing Authorisation under Form CT 23 for Bevqolva®, a bevacizumab biosimilar indicated for metastatic carcinoma of the colon or rectum. The authorisation permits manufacture at CuraTeQ’s facility in Hyderabad and marketing of Bevqolva® in 100 mg/4mL and 400 mg/16 mL vial presentations.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Krishna Institute of Medical Sciences Ltd is ₹761.65 as of 2026-05-15.
The market capitalisation of Krishna Institute of Medical Sciences Ltd is ₹30,474.58 as of 2026-05-15.
The 1-year return of Krishna Institute of Medical Sciences Ltd is 0.00% as of 2026-05-15.
The P/E ratio of Krishna Institute of Medical Sciences Ltd is 66.51 as of 2026-05-16.
The 52-week high and low of Krishna Institute of Medical Sciences Ltd are ₹798.40 and ₹575.80, respectively, as of 2026-05-15.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
